Transcript of Feel better Live longer To improve quality of life (symptoms) To reduce mortality To reduce...
- Slide 1
- Slide 2
- Feel better Live longer
- Slide 3
- To improve quality of life (symptoms) To reduce mortality To
reduce morbidity To reduce progression of disease and induce
regression.
- Slide 4
- Left ventricular function Number of coronary arteries with
significant stenosis Extent of jeoporized myocardium
- Slide 5
- Risk stratification Noninvasive testing Cardiac
catheterization
- Slide 6
- Physical exam CXR Echocardiogram
- Slide 7
- History Baseline Electrocardiogram Exercise Testing
- Slide 8
- Class I Class II Class III Class IV Angina only with extreme
exertion Angina with walking 1 to 2 blocks Angina with walking 1
block Angina with minimal activity
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Hypertension Smoking Dyslipidemia Diabetes Mellitus Obesity
Stress Homocysteine
- Slide 13
- Treatment of Chronic Stable Angina Medical Revascularization
PCIACBG
- Slide 14
- Medical Treatment
- Slide 15
- Slide 16
- ANTIPLATELETS BETA BLOCKERS NITRATES CALCIUM ANTAGONIST ACEI
STATINS NEW THERAPIES
- Slide 17
- Effect on myocardium Effect on cardiac conduction system Effect
on coronary/systemic arteries Effect on venous capitance system
Circadian rhytm
- Slide 18
- Slide 19
- 1. Aspirin in the absence of contraindications A 2.
Beta-blockers as initial therapy in the absence of
contraindications in patients with prior myocardial infarction or
without prior myocardial infarction A,B 3. ACE inhibitor in all
patients with CAD who also have diabetes and/or LV systolic
dysfunction A 4. LDL-lowering therapy in patients with documented
or suspected CAD and LDL cholesterol >130 mg/dl, with a target
LDL of
- Slide 20
- 1. Clopidogrel when aspirin is absolutely contraindicated 2.
Long-acting non-dihydropyridine calcium antagonists instead of beta
blockers as initial therapy B 3. In patients with documented or
suspected CAD and LDL cholesterol 100129 mg/dl, several therapeutic
options are available: B a. Lifestyle and/or drug therapies to
lower LDL to
- Slide 21
- Decrease myocardial oxygen consumption Blunt exercise response
Beta-one drugs have theoretical advantage Try to avoid drugs with
intrinsic sympathomimetic activity First line therapy in all
patients with angina if possible
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Bronchospasm Diminished exercise capacity Negative inotropy
Sexual dysfunction Bradyarrhythmia Masking of hypoglycemia
Increased claudication Hair loss
- Slide 26
- Propranolol Atenolol Metoprolol Carvediloll
- Slide 27
- Slide 28
- Arterial dilation/after-load reduction Coronary arterial
vasodilation Prevention of coronary vasoconstriction Enhancement of
coronary collateral flow Improved subendocardial perfusion Slowing
of heart rate with diltiazem, verapamil
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Palpitations Headache Ankle edema Gingival hyperplasia
- Slide 33
- Verapamil Diltiazem Nifedipine Nicardipine Amlodipine
Felodipine Nisoldipine Bepridil
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Nitric oxide has been identified as endothelium-derived
relaxing factor Organic nitrates are therapeutic precursors of
endothelium-derived relaxing factor
- Slide 38
- Venous vasodilation/pre-load reduction Arterial
dilation/after-load reduction Coronary arterial vasodilation
Prevention of coronary vasoconstriction Enhancement of coronary
collateral flow Antiplatelet and antithrombotic effects
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Smaller doses Less frequent dosing Avoidance of long-acting
formulations unless a prolonged nitrate-free interval is provided
Build-in a nitrate-free interval o 8-12 hours
- Slide 44
- Headache Flushing Palpitations Tolerance
- Slide 45
- Isorbide dinitrate Isorbide mononitrate Long-acting transdermal
patches Nitroglycerin sl
- Slide 46
- Slide 47
- Slide 48
- 1. Treatment of hypertension according to Joint National
Conference VI guidelines A 2. Smoking cessation therapy B 3.
Management of diabetes C 4. Comprehensive cardiac rehabilitation
program (including exercise) B 5. LDL-lowering therapy in patients
with documented or suspected CAD and LDL cholesterol 100 mg/dl,
with a target LDL of
- Slide 49
- Smoking Complete cessation Blood pressure
- Slide 50
- CABG
- Slide 51
- Slide 52
- 1. CABG for patients with significant left main coronary
disease A 2. CABG for patients with triple-vessel disease. The
survival benefit is greater in patients with abnormal LV function
(ejection fraction